Dr John Gong, CEO of 3D Medicines, shares the company’s ‘3D – diagnostics, data, and drug development’ approach to cancer precision medicine; his philosophy of putting patient needs at the core of the company; the innovation behind their flagship product, a subcutaneous injection PD-L1 antibody that is also stable at room temperature; and his mission to commercialize this product on global markets in the next few years.
In the longer term, China will become a major player in the global pharma industry and that is good for both Chinese people and people globally.
